All In Biotech

Drug Trial Radar · NCT05599191

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-Label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough, Including Unexplained Chronic Cough (CALM-1)

Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 957 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

957

Actual

Start

Oct 25, 2022

Primary completion

Dec 17, 2025

Study completion Jun 18, 2026

Sponsor

Sponsor type
Industry
First posted
Oct 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Conditions

  • Cough
  • Refractory Chronic Cough

Interventions

  • BLU-5937Drug

    Oral administration of BLU-5937 Tablets

  • PlaceboDrug

    Oral administration of matching placebo for BLU-5937 Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 24-Hour Cough FrequencyTime frame: Week 12
  2. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) up to Week 52Time frame: Up to Week 52
  3. Number of Participants with Adverse Events of Medical Interest (AEMIs) up to Week 52Time frame: Up to Week 52
  4. Number of Participants with Study Treatment Discontinuation due to AEs and SAEs up to Week 52Time frame: Up to Week 52
  5. Number of Participants with AEs and SAEs Leading to Study Withdrawal up to Week 52Time frame: Up to Week 52
  6. Change from Baseline in Vital Signs: Systolic and Diastolic Blood Pressure (millimeters of mercury [mm Hg]) at Week 52Time frame: Baseline, Week 52
  7. Change from Baseline in Vital Sign: Pulse (beats per minute) at Week 52Time frame: Baseline, Week 52
  8. Change from Baseline in Vital Sign: Respiratory Rate (breaths per minute) at Week 52Time frame: Baseline, Week 52
  9. Change from Baseline in Vital Sign: Body Temperature (degrees Celsius) at Week 52Time frame: Baseline, Week 52
  10. Change from Baseline in Vital Sign: Weight (kilograms [kg]) at Week 52Time frame: Baseline, Week 52
  11. Change from Baseline in Male Reproductive Hormone: Total Testosterone (nanomoles per liter [nmol/L]) at Week 52Time frame: Baseline, Week 52
  12. Change from Baseline in Male Reproductive Hormones: Follicle-Stimulating Hormone [FSH] and Luteinizing Hormone [LH] (international units per liter [IU/L]) at Week 52Time frame: Baseline, Week 52
  13. Change from Baseline in Male Reproductive Hormone: Inhibin B (nanograms per liter [ng/L]) at Week 52Time frame: Baseline, Week 52
  14. Change from Baseline in Hematology Parameter: Red Blood Cell (RBC) Count (10^12 cells per liter) at Week 52Time frame: Baseline, Week 52
  15. Change from Baseline in Hematology Parameters: Hemoglobin and Mean Corpuscular Hemoglobin Concentration (MCHC) (grams per liter [g/L]) at Week 52Time frame: Baseline, Week 52
  16. Change from Baseline in Hematology Parameter: Hematocrit (percentage) at Week 52Time frame: Baseline, Week 52
  17. Change from Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV) (femtoliters [fL]) at Week 52Time frame: Baseline, Week 52
  18. Change from Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH) (picograms per cell [pg/cell]) at Week 52Time frame: Baseline, Week 52
  19. Change from Baseline in Hematology Parameter: Red Cell Distribution Width (RDW) (percentage) at Week 52Time frame: Baseline, Week 52
  20. Change from Baseline in Hematology Parameters: White Blood Cell (WBC) Count (neutrophils, lymphocytes, monocytes, eosinophils, and basophils) and Platelet Count (10^9 cells per liter) at Week 52Time frame: Baseline, Week 52
  21. Change from Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma-Glutamyl Transferase (GGT) (units per liter [U/L]) at Week 52Time frame: Baseline, Week 52
  22. Change from Baseline in Clinical Chemistry Parameters: Alkaline Phosphatase (ALP) and Creatine Kinase (CK) (international units per liter [IU/L]) at Week 52Time frame: Baseline, Week 52
  23. Change from Baseline in Clinical Chemistry Parameters: Total Bilirubin, Direct and Indirect Bilirubin, and Creatinine (micromoles per liter) at Week 52Time frame: Baseline, Week 52
  24. Change from Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Chloride, Calcium, Magnesium, Bicarbonate, Glucose, and Blood Urea Nitrogen (BUN) (millimoles per liter [mmol/L]) at Week 52Time frame: Baseline, Week 52
  25. Change from Baseline in Clinical Chemistry Parameters: Protein and Albumin (grams per liter [g/L]) at Week 52Time frame: Baseline, Week 52
  26. Change from Baseline in Clinical Chemistry Parameter: Estimated Glomerular Filtration Rate (eGFR) (milliliters per minute per 1.73 meters squared [mL/min/1.73 m^2]) at Week 52Time frame: Baseline, Week 52
  27. Change from Baseline in Clinical Chemistry Parameters: Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) (seconds) at Week 52Time frame: Baseline, Week 52
  28. Change from Baseline in Electrocardiogram (ECG) Value: Heart Rate (beats per minute) at Week 52Time frame: Baseline, Week 52
  29. Change from Baseline in ECG Value: PR Interval, QT Interval, RR Interval, QRS Interval, and Corrected QT Interval Using Fridericia's Formula (QTcF) (milliseconds) at Week 52Time frame: Baseline, Week 52

Locations

200 sites in 15 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Jasper, Alabama

  • GSK Investigational Site

    Litchfield Park, Arizona

  • GSK Investigational Site

    Scottsdale, Arizona

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    Encinitas, California

  • GSK Investigational Site

    Mission Viejo, California

  • GSK Investigational Site

    Paramount, California

  • GSK Investigational Site

    Roseville, California

  • GSK Investigational Site

    Aurora, Colorado

  • GSK Investigational Site

    Colorado Springs, Colorado

  • GSK Investigational Site

    Clearwater, Florida

  • GSK Investigational Site

    Gainesville, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Lawrenceville, Georgia

  • GSK Investigational Site

    Normal, Illinois

  • GSK Investigational Site

    Oak Lawn, Illinois

  • GSK Investigational Site

    Ames, Iowa

  • GSK Investigational Site

    Iowa City, Iowa

  • GSK Investigational Site

    Kansas City, Kansas

  • GSK Investigational Site

    Topeka, Kansas

  • GSK Investigational Site

    Wichita, Kansas

  • GSK Investigational Site

    Crowley, Louisiana

  • GSK Investigational Site

    Shreveport, Louisiana

  • GSK Investigational Site

    Annapolis, Maryland

  • GSK Investigational Site

    North Dartmouth, Massachusetts

  • GSK Investigational Site

    Ann Arbor, Michigan

  • GSK Investigational Site

    Ypsilanti, Michigan

  • GSK Investigational Site

    Columbia, Missouri

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Missoula, Montana

  • GSK Investigational Site

    Jersey City, New Jersey

  • GSK Investigational Site

    The Bronx, New York

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Raleigh, North Carolina

  • GSK Investigational Site

    Rocky Mount, North Carolina

Showing 40 of 200 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.